{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:08:34Z","timestamp":1790035714389,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40487-025-00412-9","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T19:37:38Z","timestamp":1768851458000},"page":"173-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment Strategies in Metastatic Castration-Resistant Prostate Cancer: A Narrative Review of Considerations in the Post-ARTA, Post-Docetaxel Setting"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9132-4075","authenticated-orcid":false,"given":"Kenrick","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birth-Lynn","family":"Tyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruni","family":"Ghose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Kassamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"El Debri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Shamash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"412_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-020-00119-z","author":"K Ng","year":"2020","unstructured":"Ng K, Smith S, Shamash J. Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting. Oncol Ther. 2020. https:\/\/doi.org\/10.1007\/s40487-020-00119-z.","journal-title":"Oncol Ther"},{"issue":"12","key":"412_CR2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132\u201342.","journal-title":"N Engl J Med"},{"issue":"10336","key":"412_CR3","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase\u00a03 study with a 2\u2009\u00d7\u20092 factorial design. Lancet. 2022;399(10336):1695\u2013707.","journal-title":"Lancet"},{"issue":"4","key":"412_CR4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352\u201360.","journal-title":"N Engl J Med"},{"issue":"32","key":"412_CR5","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase\u00a0III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974\u201386.","journal-title":"J Clin Oncol"},{"issue":"1","key":"412_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13\u201324.","journal-title":"N Engl J Med"},{"issue":"36","key":"412_CR7","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad F, Vjaters E, Shore N, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase\u00a0III ARANOTE trial. J Clin Oncol. 2024;42(36):4271\u201381.","journal-title":"J Clin Oncol"},{"issue":"26","key":"412_CR8","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381(26):2506\u201318.","journal-title":"N Engl J Med"},{"issue":"12","key":"412_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"22","key":"412_CR10","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091\u2013102.","journal-title":"N Engl J Med"},{"issue":"2","key":"412_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","volume":"27","author":"SJ Freedland","year":"2024","unstructured":"Freedland SJ, Davis M, Epstein AJ, Arondekar B, Ivanova JI. Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis. 2024;27(2):327\u201333.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"412_CR12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","volume":"185","author":"S Gillessen","year":"2023","unstructured":"Gillessen S, Bossi A, Davis ID, et al. Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023;185:178\u2013215.","journal-title":"Eur J Cancer"},{"issue":"9747","key":"412_CR13","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147\u201354.","journal-title":"Lancet"},{"issue":"10276","key":"412_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase\u00a02 trial. Lancet. 2021;397(10276):797\u2013804.","journal-title":"Lancet"},{"issue":"1","key":"412_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Emmett L, Sandhu S, et al. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25(1):99\u2013107.","journal-title":"Lancet Oncol"},{"issue":"1","key":"412_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2967\/jnumed.124.268807","volume":"66","author":"M Wenzel","year":"2025","unstructured":"Wenzel M, Koll F, Hoeh B, et al. Real-world comparison of cabazitaxel versus 177Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer. J Nucl Med. 2025;66(1):61\u20136.","journal-title":"J Nucl Med"},{"key":"412_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115226","volume":"217","author":"H Bolek","year":"2025","unstructured":"Bolek H, Yazgan SC, Ceylan F, et al. Comparison of two alternative sequences with cabazitaxel and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: a retrospective multicenter study (LuCaS). Eur J Cancer. 2025;217:115226.","journal-title":"Eur J Cancer"},{"issue":"3","key":"412_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213\u201323.","journal-title":"N Engl J Med"},{"key":"412_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.789319","volume":"12","author":"J Chen","year":"2021","unstructured":"Chen J, Zhang Y, Zhang X, et al. Comparison of systemic treatments for metastatic castration-resistant prostate cancer after docetaxel failure: a systematic review and network meta-analysis. Front Pharmacol. 2021;12:789319.","journal-title":"Front Pharmacol"},{"key":"412_CR20","doi-asserted-by":"publisher","first-page":"S12592024","DOI":"10.1016\/j.annonc.2024.08.2314","volume":"35","author":"V Conteduca","year":"2024","unstructured":"Conteduca V. Open-label, multicentre randomised trial of radium223-docetaxel versus docetaxel-radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation. Ann Oncol. 2024;35:S12592024.","journal-title":"Ann Oncol"},{"key":"412_CR21","doi-asserted-by":"crossref","unstructured":"Baumgarten J, Groener D, Nguyen Ngoc C, et al. Safety and efficacy of. Cancers (Basel). 2022;14(3):557.","DOI":"10.3390\/cancers14030557"},{"issue":"1","key":"412_CR22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00345-024-05188-7","volume":"42","author":"M Hommerding","year":"2024","unstructured":"Hommerding M, Hommerding O, Bernhardt M, et al. Real-world data on the prevalence of BRCA1\/2 and HRR gene mutations in patients with primary and metastatic castration resistant prostate cancer. World J Urol. 2024;42(1):491.","journal-title":"World J Urol"},{"issue":"5","key":"412_CR23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.23.00339","volume":"42","author":"J Mateo","year":"2024","unstructured":"Mateo J, de Bono JS, Fizazi K, et al. Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial. J Clin Oncol. 2024;42(5):571\u201383.","journal-title":"J Clin Oncol"},{"issue":"3","key":"412_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","volume":"84","author":"W Abida","year":"2023","unstructured":"Abida W, Campbell D, Patnaik A, et al. Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase\u00a02 TRITON2 study. Eur Urol. 2023;84(3):321\u201330.","journal-title":"Eur Urol"},{"issue":"28","key":"412_CR25","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","volume":"35","author":"S Oudard","year":"2017","unstructured":"Oudard S, Fizazi K, Sengel\u00f8v L, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase\u00a0III trial-FIRSTANA. J Clin Oncol. 2017;35(28):3189\u201397.","journal-title":"J Clin Oncol"},{"issue":"6","key":"412_CR26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/bco2.177","volume":"3","author":"ND James","year":"2022","unstructured":"James ND, Ali A, Pope A, et al. Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer. BJUI Compass. 2022;3(6):484\u201393.","journal-title":"BJUI Compass"},{"key":"412_CR27","doi-asserted-by":"publisher","unstructured":"Barata PC, Corrigan J, Culnan J, et al. Docetaxel rechallenge versus cabazitaxel in patients previously treated with docetaxel for metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol. 2025;43(5_suppl):154. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.154.","DOI":"10.1200\/JCO.2025.43.5_suppl.154"},{"issue":"2","key":"412_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","volume":"14","author":"PL Kellokumpu-Lehtinen","year":"2013","unstructured":"Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase\u00a03 trial. Lancet Oncol. 2013;14(2):117\u201324.","journal-title":"Lancet Oncol"},{"issue":"13","key":"412_CR29","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","volume":"19","author":"AM Aparicio","year":"2013","unstructured":"Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19(13):3621\u201330.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"412_CR30","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","volume":"20","author":"PG Corn","year":"2019","unstructured":"Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase\u00a01-2 trial. Lancet Oncol. 2019;20(10):1432\u201343.","journal-title":"Lancet Oncol"},{"issue":"1","key":"412_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00280-012-1896-9","volume":"70","author":"N Kentepozidis","year":"2012","unstructured":"Kentepozidis N, Soultati A, Giassas S, et al. Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase\u00a0II study. Cancer Chemother Pharmacol. 2012;70(1):161\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"412_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/sj.bjc.6602263","volume":"92","author":"J Shamash","year":"2005","unstructured":"Shamash J, Dancey G, Barlow C, Wilson P, Ansell W, Oliver RT. Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. Br J Cancer. 2005;92(1):36\u201340.","journal-title":"Br J Cancer"},{"issue":"8","key":"412_CR33","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/cncr.11713","volume":"98","author":"LM Glode","year":"2003","unstructured":"Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer. 2003;98(8):1643\u20138.","journal-title":"Cancer"},{"issue":"8","key":"412_CR34","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/sj.bjc.6602177","volume":"91","author":"AJ Birtle","year":"2004","unstructured":"Birtle AJ, Newby JC, Harland SJ. Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer. Br J Cancer. 2004;91(8):1472\u20136.","journal-title":"Br J Cancer"},{"issue":"12","key":"412_CR35","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","volume":"20","author":"DJ Khalaf","year":"2019","unstructured":"Khalaf DJ, Annala M, Taavitsainen S, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase\u00a02, crossover trial. Lancet Oncol. 2019;20(12):1730\u20139.","journal-title":"Lancet Oncol"},{"issue":"3","key":"412_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3109\/21681805.2013.860189","volume":"48","author":"FB Thomsen","year":"2014","unstructured":"Thomsen FB, R\u00f8der MA, Rathenborg P, Brasso K, Borre M, Iversen P. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scand J Urol. 2014;48(3):268\u201375.","journal-title":"Scand J Urol"},{"issue":"2","key":"412_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.eururo.2014.07.028","volume":"68","author":"K Brasso","year":"2015","unstructured":"Brasso K, Thomsen FB, Schrader AJ, et al. Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis. Eur Urol. 2015;68(2):317\u201324.","journal-title":"Eur Urol"},{"issue":"1","key":"412_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.eururo.2017.03.007","volume":"72","author":"MR Smith","year":"2017","unstructured":"Smith MR, Saad F, Rathkopf DE, et al. Clinical outcomes from androgen signaling-directed therapy after treatment with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. Eur Urol. 2017;72(1):10\u20133.","journal-title":"Eur Urol"},{"issue":"7","key":"412_CR39","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1093\/annonc\/mdt138","volume":"24","author":"KL Noonan","year":"2013","unstructured":"Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24(7):1802\u20137.","journal-title":"Ann Oncol"},{"issue":"7","key":"412_CR40","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1470-2045(25)00209-8","volume":"26","author":"N Agarwal","year":"2025","unstructured":"Agarwal N, Azad AA, Carles J, et al. Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase\u00a03, open-label, randomised trial. Lancet Oncol. 2025;26(7):860\u201376.","journal-title":"Lancet Oncol"},{"key":"412_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf025","author":"NJ Altomare","year":"2025","unstructured":"Altomare NJ, Li Y, Neill C, Hussain M, VanderWeele DJ. Response to pembrolizumab in advanced prostate cancer with predictive biomarkers. Oncologist. 2025. https:\/\/doi.org\/10.1093\/oncolo\/oyaf025.","journal-title":"Oncologist"},{"issue":"5","key":"412_CR42","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase\u00a0II KEYNOTE-199 study. J Clin Oncol. 2020;38(5):395\u2013405.","journal-title":"J Clin Oncol"},{"key":"412_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001065","author":"P Barata","year":"2020","unstructured":"Barata P, Agarwal N, Nussenzveig R, et al. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-001065.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"412_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25(2):175\u201383.","journal-title":"Lancet Oncol"},{"issue":"4","key":"412_CR45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","volume":"24","author":"LB Snyder","year":"2025","unstructured":"Snyder LB, Neklesa TK, Willard RR, et al. Preclinical evaluation of bavdegalutamide (ARV-110), a novel PROteolysis TArgeting Chimera androgen receptor degrader. Mol Cancer Ther. 2025;24(4):511\u201322.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"412_CR46","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","volume":"36","author":"DE Rathkopf","year":"2025","unstructured":"Rathkopf DE, Patel MR, Choudhury AD, et al. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025;36(1):76\u201388.","journal-title":"Ann Oncol"},{"issue":"2","key":"412_CR47","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/imt-2020-0256","volume":"13","author":"HD Hummel","year":"2021","unstructured":"Hummel HD, Kufer P, Gr\u00fcllich C, et al. Pasotuxizumab, a BiTE. Immunotherapy. 2021;13(2):125\u201341.","journal-title":"Immunotherapy"},{"key":"412_CR48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00678","author":"MN Stein","year":"2025","unstructured":"Stein MN, Vinceneux A, Robbrecht D, et al. Pasritamig, a first-in-class, bispecific T-cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: a phase\u00a0I study. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO-25-00678.","journal-title":"J Clin Oncol"},{"issue":"6","key":"412_CR49","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","volume":"30","author":"TB Dorff","year":"2024","unstructured":"Dorff TB, Blanchard MS, Adkins LN, et al. PSCA-CAR T\u00a0cell therapy in metastatic castration-resistant prostate cancer: a phase\u00a01 trial. Nat Med. 2024;30(6):1636\u201344.","journal-title":"Nat Med"},{"issue":"2","key":"412_CR50","volume":"15","author":"M Sardinha","year":"2023","unstructured":"Sardinha M, Palma Dos Reis AF, Barreira JV, Fontes Sousa M, Pacey S, Luz R. Antibody-drug conjugates in prostate cancer: a systematic review. Cureus. 2023;15(2):e34490.","journal-title":"Cureus"},{"issue":"24","key":"412_CR51","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain M, Mateo J, Fizazi K, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345\u201357.","journal-title":"N Engl J Med"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00412-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00412-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00412-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:04:13Z","timestamp":1773673453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00412-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["412"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00412-9","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No assistance for medical writing was received.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical Writing\/Editorial Assistance"}},{"value":"Kenrick Ng has received advisory board and speaker fees from Pfizer, AstraZeneca, Bayer, and UCB Pharmaceuticals, and research funding from Prostate Cancer Research. Kenrick Ng is an Editor-in-Chief of\n                      Oncology and Therapy\n                      . Kenrick Ng was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Jonathan Shamash has received speaker fees from Bayer. The remaining authors (Birth-Lynn Tyers, Aruni Ghose, Abbas Kassamali and Reem El Debri) declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}